A Study to Evaluate Rucaparib in Patients with Solid Tumors and with Deleterious Mutations in HRR Genes (LODESTAR)
https://www.facingourrisk.org/research-clinical-trials/study/88/a-study-to-evaluate-rucaparib-in-patients-with-solid-tumors-and-with-deleterious-mutations-in-hrr-genes
Clinicaltrials.gov identifier:
NCT04171700 (https://clinicaltrials.gov/show/NCT04171700)
Study Contact Information:
Principal Investigator:
Kim Reiss-Binder, MD
University of Pennsylvania
About the Study
The LODESTAR study is evaluating the response of the PARP inhibitor rucaparib in people with advanced solid tumors (including breast, ovarian, pancreatic, prostate and other cancers) who have an inherited mutation or an acquired mutation in any of the following genes: BRCA1, BRCA2, PALB2, RAD51C, RAD51D, BARD1, BRIP1, FANCA, NBN, RAD51 or RAD51B. NOTE: This study is no longer enrolling people.
This Study is Open To:
NOTE: This study is no longer enrolling people.
This Study is Not Open To:
NOTE: This study is no longer enrolling people.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.